Today's Portrait Highlights

Innovation Skåne AB: Increased efficiency and quality in the healthcare through innovation

Innovation Skåne AB supports entrepreneurs in the development of fast-growing companies and contributes to increased efficiency and quality in the healthcare through innovation. Our HealthTech Arena is a test bed and meeting place where Innovative HealthTech companies have the opportunity to test and validate their e-health products and services against real needs in the healthcare sector, from product idea and onwards. Services include idea testing, IT testing and usability, and, moreover, Innovation Skåne provides access to clinical trials through its sister organisation.

Sentiero logistiq

Sentiero logistiq is a consulting and engineering company, based on company activities starting from 1989.The company today is located in Hamburg with a Baltic Sea region partner office in Vilnius. From its early beginnings, sentiero logistiq dedicated its resources towards the logistics and supply chain services in combination with It-services. The long time experience in logistics and supply chain services, infrastructure and special healthcare logistics, will be combined with experience in technical solutions, security and management systems. Healthcare Logistics i. e. pharmaceutical logistics and supply chain as well as specific solutions for Hospital Logistics and Transports are parts of the company services since 1993. The outcomes of the companies services are innovative solutions related to customer requirements and customer organization specific processes and – always with a focus on sustainability.

DelSiTech Ltd

DelSiTech is an innovative Finnish drug delivery technology company that helps its customers to turn their active agents into novel and commercially viable therapeutic drug products. DelSiTech offers one-stop shop opportunity in drug delivery up to early clinical proof of concept. The Company’s proprietary drug delivery technology is based on biodegradable silica (SiO2) matrix into which the active ingredient is embedded. The matrix can be designed to biodegrade at the required rate to assure a tightly controlled release of the active substance, providing a better therapeutic effect in situ and causing lower systemic and local adverse effects than alternative delivery systems. DelSiTech also develops its own supergeneric drug products to address significant unmet medical and commercial needs. The lead product, 1308 is a long-acting subcutaneous depot injection that offers for the first time a patient-friendly slow release treatment option to chronic hepatitis B infection.